These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817 [TBL] [Abstract][Full Text] [Related]
6. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266 [TBL] [Abstract][Full Text] [Related]
7. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade. Skanes AC; Morton BC; Green MS; Tang AS Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970 [TBL] [Abstract][Full Text] [Related]
8. Drugs, QT interval abnormalities and ventricular arrhythmias. Thomas SH Adverse Drug React Toxicol Rev; 1994; 13(2):77-102. PubMed ID: 7918900 [No Abstract] [Full Text] [Related]
9. Drug-induced torsade de pointes. Incidence, management and prevention. Faber TS; Zehender M; Just H Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055 [TBL] [Abstract][Full Text] [Related]
10. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. Shah SA; Kluger J; White CM Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083 [TBL] [Abstract][Full Text] [Related]
11. [The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe?]. Pelov R; Tankova L; Krushkov I Vutr Boles; 1999; 31(2-3):5-9. PubMed ID: 10847134 [TBL] [Abstract][Full Text] [Related]
12. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling. Vos MA; Crijns HJ Anadolu Kardiyol Derg; 2001 Mar; 1(1):27-34. PubMed ID: 12122969 [TBL] [Abstract][Full Text] [Related]
14. What have clinical trials taught us about proarrhythmia? Skanes AC; Green MS Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725 [TBL] [Abstract][Full Text] [Related]
16. Reproducible induction of "atypical" torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia? Krishnan SC; Galvin J; McGovern B; Garan H; Ruskin JN J Cardiovasc Electrophysiol; 1997 Sep; 8(9):1055-61. PubMed ID: 9300303 [TBL] [Abstract][Full Text] [Related]
17. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Layton D; Key C; Shakir SA Pharmacoepidemiol Drug Saf; 2003; 12(1):31-40. PubMed ID: 12616845 [TBL] [Abstract][Full Text] [Related]
18. [Cardiac arrest following treatment with non-cardiologic QT-interval-increasing medications]. Al-Amood S; Elming H Ugeskr Laeger; 2005 May; 167(18):1966-8. PubMed ID: 15929273 [No Abstract] [Full Text] [Related]
19. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. Kühlkamp V; Mermi J; Mewis C; Seipel L J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676 [TBL] [Abstract][Full Text] [Related]
20. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]